Biophytis Dirección

Dirección controles de criterios 4/4

El CEO de Biophytis es Stanislas Veillet , nombrado en May 2015, tiene una permanencia de 9.5 años. compensación anual total es €349.00K, compuesta por 71.6% salario y 28.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.9% de las acciones de la empresa, por valor de €13.78K. La antigüedad media del equipo directivo y de la junta directiva es de 5.1 años y 5.2 años, respectivamente.

Información clave

Stanislas Veillet

Chief Executive Officer (CEO)

€349.0k

Compensación total

Porcentaje del salario del CEO	71.6%
Permanencia del CEO	9.5yrs
Participación del CEO	0.9%
Permanencia media de la dirección	5.1yrs
Promedio de permanencia en la Junta Directiva	5.2yrs

Actualizaciones recientes de la dirección

Recent updates

Biophytis (EPA:ALBPS) Has Debt But No Earnings; Should You Worry?

Nov 18

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Stanislas Veillet en comparación con los beneficios de Biophytis?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-€15m
Mar 31 2024	n/a	n/a	-€16m
Dec 31 2023	€349k	€250k	-€17m
Sep 30 2023	n/a	n/a	-€18m
Jun 30 2023	n/a	n/a	-€20m
Mar 31 2023	n/a	n/a	-€22m
Dec 31 2022	€428k	€250k	-€24m
Sep 30 2022	n/a	n/a	-€27m
Jun 30 2022	n/a	n/a	-€30m
Mar 31 2022	n/a	n/a	-€31m
Dec 31 2021	€460k	€250k	-€31m
Sep 30 2021	n/a	n/a	-€28m
Jun 30 2021	n/a	n/a	-€25m
Mar 31 2021	n/a	n/a	-€25m
Dec 31 2020	€374k	€250k	-€26m
Sep 30 2020	n/a	n/a	-€24m
Jun 30 2020	n/a	n/a	-€22m
Mar 31 2020	n/a	n/a	-€22m
Dec 31 2019	€310k	€250k	-€19m
Sep 30 2019	n/a	n/a	-€19m
Jun 30 2019	n/a	n/a	-€18m
Mar 31 2019	n/a	n/a	-€15m
Dec 31 2018	€295k	€225k	-€14m
Sep 30 2018	n/a	n/a	-€13m
Jun 30 2018	n/a	n/a	-€12m
Mar 31 2018	n/a	n/a	-€12m
Dec 31 2017	€447k	€150k	-€11m

Compensación vs. Mercado: La compensación total ($USD369.08K) de Stanislas está en línea con el promedio de empresas de tamaño similar en el mercado French ($USD307.69K).

Compensación vs. Ingresos: La compensación de Stanislas ha sido consistente con los resultados de la empresa en el último año.

CEO

Stanislas Veillet (59 yo)

9.5yrs

Permanencia

€349,000

Compensación

Mr. Stanislas Veillet, Ph D., serves as Chairman of the Board and Chief Executive Officer of Biophytis SA since May 22, 2015. Mr. Veillet is the Co-founder of Biophytis (created in 2006) and served as its...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stanislas Veillet	Chairman of the Board & CEO	9.5yrs	€349.00k	0.90% € 13.8k
Waly Dioh	Chief Clinical Operating Officer	5.1yrs	sin datos	0.0060% € 92.2
Pierre Dilda	Chief Scientific Officer	5.1yrs	sin datos	0.0032% € 48.3
Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	5.2yrs	sin datos	sin datos
Rob van Maanen	Chief Medical Officer	3.2yrs	sin datos	0% € 0
Edouard Bieth	Chief Business Officer	1.2yrs	sin datos	sin datos
Chiara Baccelli	Chief Pharmaceutical Operations Officer & Quality Assurance Director	1.8yrs	sin datos	0% € 0
_ Teylan	Financial Controller	no data	sin datos	sin datos

5.1yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ALBPS es experimentado (5.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stanislas Veillet	Chairman of the Board & CEO	9.5yrs	€349.00k	0.90% € 13.8k
Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	5.2yrs	sin datos	sin datos
Claude Allary	Independent Director	3.3yrs	€25.00k	0% € 0
Jose-Alain Sahel	Member of Scientific Advisory Board	no data	sin datos	sin datos
Thomas Voit	Member of Scientific Advisory Board	7.1yrs	sin datos	sin datos
Roger Fielding	Member of Scientific Advisory Board	8.5yrs	sin datos	sin datos
Jean Mariani	Chairman of Scientific Advisory Board & Director	8.6yrs	€25.00k	0% € 0
Nadine Coulm	Independent Director	9.5yrs	€25.00k	0.000060% € 0.9
Yann Meunier	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Bernard Levy	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Dennis Villareal	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Francisco Guarner	Member of Scientific Advisory Board	less than a year	sin datos	sin datos

5.2yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: La junta directiva de ALBPS se considera experimentada (5.2 años de antigüedad promedio).

Biophytis Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis S.A. Announces Executive Changes

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Recent updates

Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Announces the Publication of the Results of its COVA Phase 2-3 Study in eClinicalMedicine, Part of The Lancet

Biophytis S.A. and the University of Li Ge Explore the Potential of Sarconeos (BIO101) in the Treatment of Viral Respiratory Diseases

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis Receives Notice of Delisting from Nasdaq and Announces It Will Request A Hearing Before the Nasdaq Hearings Panel

Biophytis S.A. Provides an Update on the Progress of its R&D Projects over the 1St Half of the Year and the Last Few Months

Biophytis SA Provides Update on its Early Access Programs for Sarconeos (BIO101) in Treatment of Severe Forms of COVID-19

Biophytis SA Receives Response from the French National Authority for Health to Request for Early Access Authorization in France for Patients Suffering from Severe Forms of COVID-19

Biophytis S.A. Announces Executive Changes

Biophytis Obtains Fda Authorization to Initiate the Sara-31 Phase 3 Study in Sarcopenia

Biophytis SA Announces Next Regulatory Steps in Europe and the United States for its COVA Project

Biophytis SA Receives Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

Biophytis S.A. Files for a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis and Seqens Sign A Partnership to Produce Sarconeos (Bio101) Active Compound

Biophytis SA Filed with the FDA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Biophytis SA Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Biophytis S.A. has completed a Follow-on Equity Offering in the amount of €2.302535 million.

Biophytis SA Files for Pre-Submission Meeting Request with the European Medicine Agency (EMA) to Discuss Filing for Conditional Marketing Authorisation (CMA) in Europe

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Biophytis S.A. Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis to Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19

Biophytis Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

Biophytis S.A. Announces Promising Top Line Results of Its Phase 2-3 Cova Clinical Study in COVID-19-Related Respiratory Failure

Biophytis SA to Update on the Development of Sarconeos (BIO101) in Covid-19 at 4th Annual Longevity Therapeutics Summit

Biophytis Presents the Development of Sarconeos in Phase 3 for the Treatment of Sarcopenia At the 15th SCWD International Congress

Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), A Rare Neuromuscular Disease

Biophytis SA, Annual General Meeting, Jun 03, 2022

Biophytis SA Announces Chief Financial Officer Changes

Biophytis Sa Receives Approval from the ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients Through an Expanded Access Program

Biophytis SA to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Biophytis (EPA:ALBPS) Has Debt But No Earnings; Should You Worry?

Biophytis to Present Full Results from the Sara-INT Phase 2B Trial of Sarconeos in Sarcopenia At the 11Th Annual International Conference

Biophytis SA Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 Cova Study with Sarconeos (Bio101) in Covid-19

Biophytis SA Receives Favorable Recommendation from Data Monitoring Committee Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the Cova Study in COVID-19

Independent Director Jean Franchi has left the company

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

Biophytis SA to Release Topline Results for SARA-INT Phase 2 Study in August 2021

Biophytis SA Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

BIOPHYTIS Completes Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the Second Interim Analysis

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

Biophytis SA, Annual General Meeting, Apr 26, 2021

Biophytis Sa Announces That Patient Recruitment Will Begin in France and Belgium for Part 2 of Its Cova Study Assessing Sarconeos

New 90-day high: €1.69

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial

Biophytis SA Receives DMC Recommendation for Starting Recruitment for Part 2 of Its Phase 2-3 Cova Study in COVID-19

New 90-day high: €1.32

New 90-day high: €0.74

New 90-day high: €0.71

Biophytis Enrolls First Patient in Brazil in COVA, A Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

New 90-day low: €0.39

New 90-day low: €0.51

New 90-day low - €0.62

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad